StockData
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. (JSPR) stock

JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$10.34−1.43 (-12.15%)

Close on Nov 17, 2026Market cap $344.06MP/E –Yield –

Jasper Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Jasper Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$55.16M. For fiscal 2025 it was -$83.88M. The highest annual figure on record is -$20.68M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$83.88M–
FY2024Dec 31, 2024-$76.24M–
FY2023Dec 31, 2023-$68.86M–
FY2022Dec 31, 2022-$51.20M–
FY2021Dec 31, 2021-$36.83M–
FY2020Dec 31, 2020-$20.68M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.21M–
Q1 FY2026Mar 31, 2026-$10.95M–
Q4 FY2025Dec 31, 2025-$15.84M–
Q3 FY2025Sep 30, 2025-$19.17M–
Q2 FY2025Jun 30, 2025-$27.08M–
Q1 FY2025Mar 31, 2025-$21.80M–
Q4 FY2024Dec 31, 2024-$25.29M–
Q3 FY2024Sep 30, 2024-$19.89M–
Q2 FY2024Jun 30, 2024-$15.99M–
Q1 FY2024Mar 31, 2024-$15.07M–
Q2 FY2023Jun 30, 2023-$17.83M–
Q1 FY2023Mar 31, 2023-$13.95M–
Q4 FY2022Dec 31, 2022-$13.75M–
Q3 FY2022Sep 30, 2022-$12.71M–
Q2 FY2022Jun 30, 2022-$11.96M–
Q1 FY2022Mar 31, 2022-$12.78M–
Q4 FY2021Dec 31, 2021-$12.08M–
Q3 FY2021Sep 30, 2021-$10.08M–
Q2 FY2021Jun 30, 2021-$8.42M–
Q1 FY2021Mar 31, 2021-$6.25M–
Q4 FY2020Dec 31, 2020-$5.96M–
Q3 FY2020Sep 30, 2020-$6.01M–
Q2 FY2020Jun 30, 2020-$327.56K–
Q1 FY2020Mar 31, 2020-$228.67K–

More Jasper Therapeutics figures

See a number that looks wrong?